European Treaty Series - No. 135 Anti-Doping Convention Strasbourg, 16.XI.1989 Appendix – AMENDMENTS TO THE APPENDIX (approved by the Monitoring Group under Article 11.1.b of the Convention at its 51st meeting) (Strasbourg, 24 October 2019) THE 2020 PROHIBITED LIST - WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE: 1 JANUARY 2020 SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S.4.4, S.4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES 1-Testosterone (17β-hydroxy-5α-androst-1- en-3-one); S0. NON-APPROVED SUBSTANCES 4-Androstenediol (androst-4-ene-3β,17β-diol); 4-Hydroxytestosterone (4,17β- Any pharmacological substance which is not dihydroxyandrost-4-en-3one); addressed by any of the subsequent sections of 5-Androstenedione (androst-5-ene-3,17- the List and with no current approval by any dione); governmental regulatory health authority for 7α-hydroxy-DHEA; human therapeutic use (e.g. drugs under pre- 7β-hydroxy-DHEA; clinical or clinical development or discontinued, 7-Keto-DHEA; designer drugs, substances approved only for 19-Norandrostenediol (estr-4-ene-3,17-diol); veterinary use) is prohibited at all times. 19-Norandrostenedione (estr-4-ene-3,17- dione); S1. ANABOLIC AGENTS Androstanolone (5α-dihydrotestosterone, 17β- hydroxy-5αandrostan-3-one); Anabolic agents are prohibited. Androstenediol (androst-5-ene-3β,17β-diol); …………………………………………………… Androstenedione (androst-4-ene-3,17-dione); 1. ANABOLIC ANDROGENIC STEROIDS Bolasterone; (AAS) Boldenone; Boldione (androsta-1,4-diene-3,17-dione); when administered exogenously, including but Calusterone; not limited to: Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en- 1-Androstenediol (5α-androst-1-ene-3β,17β- 20-yn-17α-ol); diol); Dehydrochlormethyltestosterone (4-chloro- 1-Androstenedione (5α-androst-1-ene-3,17- 17β-hydroxy-17α-methylandrosta-1,4-dien-3- dione); one); 1-Androsterone (3α-hydroxy-5α-androst-1- Desoxymethyltestosterone (17α-methyl-5α- ene-17-one); androst-2-en-17β-ol); 1-Epiandrosterone (3β-hydroxy-5α-androst-1- Drostanolone; ene-17-one); Epiandrosterone (3β-hydroxy-5α-androstan- 17-one); ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2020 Prohibited List _________________________________________________________________________________ Epi-dihydrotestosterone (17β-hydroxy-5β- ……………………………………………………. androstan-3one); 2. OTHER ANABOLIC AGENTS Epitestosterone; Ethylestrenol (19-norpregna-4-en-17α-ol); Including, but not limited to: Fluoxymesterone; Formebolone; Clenbuterol, selective androgen receptor Furazabol (17α-methyl modulators [SARMs, e.g. andarine, LGD-4033 [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan- (ligandrol), enobosarm (ostarine) and 17β-ol); RAD140], tibolone, zeranol and zilpaterol. Gestrinone; Mestanolone; Mesterolone; S2. PEPTIDE HORMONES, GROWTH Metandienone (17β-hydroxy-17α- FACTORS, RELATED SUBSTANCES, methylandrosta-1,4-dien-3-one); AND MIMETICS Metenolone; Methandriol; The following substances, and other Methasterone (17β-hydroxy-2α,17α-dimethyl- substances with similar chemical structure or 5α-androstan-3-one); similar biological effect(s), are prohibited: Methyl-1-testosterone (17β-hydroxy-17α- methyl-5α-androst-1-en-3-one); 1. Erythropoietins (EPO) and agents affecting Methylclostebol; erythropoiesis, including, but not limited to: Methyldienolone (17β-hydroxy-17α- methylestra-4,9-dien-3-one); 1.1 Erythropoietin-Receptor Agonists, e.g. Methylnortestosterone (17β-hydroxy-17α- Darbepoietin (dEPO); methylestr-4-en-3-one); Erythropoietins (EPO); Methyltestosterone; EPO based constructs [e.g. EPO-Fc, Metribolone (methyltrienolone, 17β-hydroxy- methoxy polyethylene glycol-epoetin 17α-methylestra-4,9,11-trien-3-one); beta (CERA)]; Mibolerone; EPO-mimetic agents and their Nandrolone (19-nortestosterone); constructs (e.g. CNTO 530, Norboletone; peginesatide). Norclostebol; Norethandrolone; 1.2 Hypoxia-inducible factor (HIF) Oxabolone; activating agents, e.g. Oxandrolone; Cobalt; Oxymesterone; Daprodustat (GSK1278863); Oxymetholone; Molidustat (BAY 85-3934); Prasterone (dehydroepiandrosterone, DHEA, Roxadustat (FG-4592); 3β-hydroxyandrost-5-en-17-one); Vadadustat (AKB-6548); Prostanozol (17β-[(tetrahydropyran-2-yl)oxy]- Xenon. 1'H-pyrazolo[3,4:2,3]-5α-androstane); Quinbolone; 1.3 GATA inhibitors, e.g. Stanozolol; K-11706. Stenbolone; Testosterone; 1.4 TGF-beta (TGF-β) signaling inhibitors, Tetrahydrogestrinone (17-hydroxy-18a-homo- e.g. Luspatercept; 19-nor-17α-pregna-4,9,11-trien-3-one); Sotatercept. Trenbolone (17β-hydroxyestr-4,9,11-trien-3- one); 1.5 Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO). and other substances with a similar chemical structure or similar biological effect(s). ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2020 Prohibited List _________________________________________________________________________________ 2. Peptide hormones and their Releasing Factors, S3. BETA-2 AGONISTS 2.1 Chorionic Gonadotrophin (CG) and All selective and non-selective beta-2 agonists, Luteinizing Hormone (LH) and their including all optical isomers, are prohibited. releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, Including, but not limited to: goserelin, leuprorelin, nafarelin and Fenoterol; triptorelin; Formoterol, Higenamine; 2.2 Corticotrophins and their releasing Indacaterol; factors, e.g Corticorelin; Olodaterol; Procaterol; 2.3 Growth Hormone (GH), its fragments Reproterol; and releasing factors, including, but Salbutamol; not limited to: Salmeterol; Growth Hormone fragments, e.g. Terbutaline; AOD-9604 and hGH 176-191; Tretoquinol (trimetoquinol); Growth Hormone Releasing Hormone Tulobuterol; (GHRH) and its analogues, e.g. Vilanterol. CJC-1293, CJC-1295, sermorelin and tesamorelin; Except: Growth Hormone Secretagogues (GHS), e.g. lenomorelin (ghrelin) and Inhaled salbutamol: maximum its mimetics, e.g. 1600 micrograms over 24 hours in divided anamorelin, ipamorelin, macimorelin doses not to exceed 800 micrograms over and tabimorelin; 12 hours starting from any dose; GH-Releasing Peptides (GHRPs), e.g. Inhaled formoterol: maximum delivered alexamorelin, GHRP-1, GHRP-2 dose 54 micrograms over 24 hours; (pralmorelin), GHRP-3, GHRP-4, Inhaled salmeterol: maximum GHRP-5, GHRP-6, and examorelin 200 micrograms over 24 hours. (hexarelin). The presence in urine of salbutamol in excess 3. Growth Factors and Growth Factor of 1000 ng/mL or formoterol in excess of Modulators, including, but not limited to: 40 ng/mL is not consistent with therapeutic use Fibroblast Growth Factors (FGFs); of the substance and will be considered as an Hepatocyte Growth Factor (HGF); Adverse Analytical Finding (AAF) unless the Insulin-like Growth Factor-1 (IGF-1) and its Athlete proves, through a controlled analogues; pharmacokinetic study, that the abnormal Mechano Growth Factors (MGFs); result was the consequence of a therapeutic Platelet-Derived Growth Factor (PDGF); dose (by inhalation) up to the maximum dose Thymosin-β4 and its derivatives e.g. TB- indicated above. 500; Vascular-Endothelial Growth Factor (VEGF). and other growth factors or growth factors modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilisation, regenerative capacity or fibre type switching. ETS 135 – Anti-Doping Convention, 16.XI.1989 - The 2020 Prohibited List _________________________________________________________________________________ S4. HORMONE AND METABOLIC 5. Metabolic modulators: MODULATORS 5.1 Activators of the AMP-activated The following hormone and metabolic protein kinase (AMPK), e.g. AICAR, modulators are prohibited: SR9009; and Peroxisome Proliferator Activated 1. Aromatase inhibitors including, but not Receptor δ (PPARδ) agonists, e.g. 2- limited to: (2-methyl-4-((4-methyl-2-(4- 2-Androstenol (5α-androst-2-en-17-ol); (trifluoromethyl)phenyl)thiazol-5- 2-Androstenone (5α-androst-2-en-17-one); yl)methylthio)phenoxy) acetic acid 3-Androstenol (5α-androst-3-en-17-ol); (GW1516, GW501516); 3-Androstenone (5α-androst-3-en-17-one); 5.2 Insulins and insulin-mimetics; 4-Androstene-3,6,17 trione (6-oxo); 5.3 Meldonium; Aminoglutethimide; 5.4 Trimetazidine. Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatrienedione); S5. DIURETICS AND MASKING AGENTS Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; The following diuretics and masking agents are Formestane; prohibited, as are other substances with a Letrozole; similar chemical structure or similar biological Testolactone. effect(s). 2. Selective estrogen receptor modulators Including, but not limited to: (SERMs) including, but not limited to: Bazedoxifene; Desmopressin; probenecid; plasma Ospemifene; expanders, e.g. intravenous administration Raloxifene; of albumin, dextran, hydroxyethyl starch Tamoxifen; and mannitol. Toremifene. Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; 3. Other anti-estrogenic substances including, furosemide; indapamide; metolazone; but not limited to: spironolactone; thiazides, e.g. Clomiphene; bendroflumethiazide, chlorothiazide and Cyclofenil; hydrochlorothiazide; triamterene and Fulvestrant. vaptans, e.g. tolvaptan. 4. Agents preventing activin receptor IIB Except: activation including, but not limited, to: Drospirenone; pamabrom; and ophtalmic use of carbonic anhydrase inhibitors (e.g. Activin A-neutralising antibodies; dorzolamide,